# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Mark Breidenbach maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price targe...
Truist Securities analyst Srikripa Devarakonda initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Buy rating and ...
JP Morgan analyst Eric Joseph maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from ...
Barclays analyst Peter Lawson maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from ...
RBC Capital analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target f...
Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $31 to $29.